Current Report Filing (8-k)
September 24 2019 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM
8-K
_________________________
CURRENT REPORT Pursuant to Section 13
or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 24, 2019
_________________________
AVADEL PHARMACEUTICALS PLC
(Exact
name of registrant as specified in its charter)
_________________________
Ireland
(State or Other Jurisdiction of
Incorporation)
|
001-37977
(Commission File Number)
|
98-1341933
(I.R.S. Employer Identification No.)
|
Block 10-1
Blanchardstown Corporate Park, Ballycoolin
Dublin 15, Ireland
(Address of Principal Executive Offices)
|
Not Applicable
(Zip Code)
|
Registrant’s
telephone number, including area code: +353 1 485 1200
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
|
Ticker
symbol(s)
|
|
Name
of each exchange on
which registered
|
American Depositary Shares*
|
|
AVDL
|
|
NASDAQ Stock Market LLC
|
Ordinary Shares**
|
|
|
|
(NASDAQ Global Market)
|
|
*
|
American Depositary Shares may be evidenced by American Depository Receipts. Each American Depositary
Share represents one (1) Ordinary Share.
|
|
**
|
Nominal value $0.01 per share. Not for trading, but only
in connection with the listing of American Depositary Shares.
|
On September 24, 2019, Avadel Pharmaceuticals plc issued a press
release, a copy of which is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AVADEL PHARMACEUTICALS PLC
|
|
|
|
|
By:
|
/s/ Phillandas T. Thompson
|
|
|
Phillandas T. Thompson
|
|
|
Senior Vice President, General Counsel and Corporate Secretary
|
Date: September 24, 2019
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2024 to May 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From May 2023 to May 2024